



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6:

C12N 9/12, C12Q 1/68

A1

(11) International Publication Number:

WO 95/16028

(43) International Publication Date:

15 June 1995 (15.06.95)

(21) International Application Number: PCT/US94/14065

(22) International Filing Date: 7 December 1994 (07.12.94)

(30) Priority Data:

164,290

8 December 1993 (08.12.93)

US

197,791

16 February 1994 (16.02.94)

US

(71) Applicant: STRATAGENE [US/US]; 11099 North Torrey Pines Road, La Jolla, CA 92037 (US).

(72) Inventors: SORGE, Joseph, A.; 17021 Circa Del Sur, Rancho Santa Fe, CA 92067 (US). MULLINAX, Rebecca, Lynn; 6198 Agce #68, San Diego, CA 92122 (US).

(74) Agents: HALLUIN, Albert, P. et al.; Pennie & Edmonds, 1155 Avenue of the Americas, New York, NY 10036 (US).

(81) Designated States: CA, JP, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).

Published

*With international search report.
Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.*

(54) Title: NOVEL POLYMERASE COMPOSITIONS AND USES THEREOF

(57) Abstract

The subject invention provides novel compositions containing a mixture of (a) an enzyme that possesses substantial 3'-5' exonuclease activity (b) a DNA polymerase with less 3'-5' exonuclease activity than the enzyme with substantial 3'-5' exonuclease activity. Preferably, the DNA polymerase for inclusion in the compositions are DNA polymerases that substantially lack 3'-5' exonuclease activity. A preferred embodiment of the invention is a composition comprising the *Taq* DNA polymerase (isolated from *Thermus aquaticus*) and the *Pfu* DNA polymerase (isolated from *Pyrococcus furiosus*). Another aspect of the invention is to provide methods for synthesizing polynucleotides, typically DNA, using compositions comprising an enzyme that possesses substantial 3'-5' exonuclease activity and a DNA polymerase with less 3'-5' exonuclease activity than the enzymes possessing substantial 3'-5' exonuclease activity, preferably a DNA polymerase that substantially lacks 3'-5' exonuclease activity. Another aspect of the invention involves the use of the subject method of polynucleotide synthesis to carry out the synthesis step in a polymerase chain reaction experiment. Yet another aspect of the invention is to provide kits for the synthesis of polynucleotides, wherein the kits comprise an enzyme that possesses substantial 3'-5' exonuclease activity and a DNA polymerase with less 3'-5' exonuclease activity than the enzyme possessing substantial 3'-5' exonuclease activity.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

NOVEL POLYMERASE COMPOSITIONS AND USES THEREOF

5 Related Applications

This application is a continuation-in-part of co-pending U.S. patent application 08/164,290 which was filed December 8, 1993.

Field of the Invention

10 The present invention is related to the field of molecular biology, and more particularly, to polynucleotide synthesis.

BACKGROUND OF THE INVENTION

DNA polymerases catalyze the synthesis of DNA and can be found in all cells as well as being encoded in numerous viruses. Although all DNA polymerases possess 5'-3' DNA polymerase activity, DNA polymerases differ from one another in numerous
15 other properties. For example, some enzymatic activities that are possessed by some DNA polymerases, but absent in other DNA polymerases include: double stranded DNA 5'-3' exonuclease activity, single-stranded DNA 3'-5' exonuclease activity, double-stranded 3'-5' DNA exonuclease activity, RNase H activity, reverse transcriptase activity, and the like. Additionally, different DNA polymerases may have different
20 optimal pH and temperature ranges for activity. Furthermore, DNA polymerases may differ in the rate in which they catalyze DNA synthesis.

Purified DNA polymerases have numerous uses in vitro. A detailed description of DNA polymerases, including methods for their isolation, can be found among other places, in DNA Replication 2nd edition, by Kornberg and Baker, W.H. Freeman &
25 Company, New York, New York 1991. In vitro uses of DNA polymerases include, for example, the labeling and synthesis of hybridization probes, DNA sequencing, and DNA amplification. A DNA amplification method employing DNA polymerases that has been particularly useful is the polymerase chain reaction (PCR) technique. The

technique of PCR is described in numerous publications, including, PCR: A Practical Approach, M.J. McPherson, et al., IRL Press (1991), PCR Protocols: A Guide to Methods and Applications, by Innis, et al., Academic Press (1990), and PCR Technology: Principles and Applications for DNA Amplification, H.A. Erlich, Stockton Press (1989). PCR is also described in many U.S. Patents, including U.S. patents, 4,683,195; 4,683,202; 4,800,159; 4,965,188; 4,889,818; 5,075,216; 5,079,352; 5,104,792; 5,023,171; 5,091,310; and 5,066,584, which are hereby incorporated by reference. The PCR technique typically involves the step of denaturing a polynucleotide, followed by the step of annealing at least a pair of primer oligonucleotides to the denatured polynucleotide, i.e., hybridizing the primer to the denatured polynucleotide template. After the annealing step, an enzyme with polymerase activity catalyzes synthesis of a new polynucleotide strand that incorporates the primer oligonucleotide and uses the original denatured polynucleotide as a synthesis template.

15 In many instances, a given DNA polymerase may fail to synthesize the desired polynucleotide product. These failures may be attributable to a number of reasons including such problems as template and primer base pair mismatches, lack of proofreading, insufficient rate of synthesis, high misincorporation rate, inability to transcribe GC or AT rich regions, lack of sufficient processivity (processivity refers to the length of synthesis product formed before the polymerase stops synthesis), etc. It is therefore of interest to provide new methods and compositions for improved polynucleotide synthesis over a wide variety of experimental conditions.

SUMMARY OF THE INVENTION

The subject invention provides novel compositions containing a mixture of (a) an enzyme that possesses substantial 3'-5' exonuclease activity and (b) a DNA polymerase with less 3'-5' exonuclease activity than the enzyme possessing substantial 3'-5' exonuclease activity. Preferably, the enzyme with substantial 3'-5' exonuclease activity is a DNA polymerase. Preferably, the DNA polymerase with less 3'-5' exonuclease activity than the enzyme possessing substantial 3'-5' exonuclease activity is a DNA polymerase substantially lacking 3'-5' exonuclease activity. When a step in a technique

of interest employing polynucleotide synthesis involves the step of incubation at an elevated temperature, e.g., PCR, both the DNA polymerase and the enzyme with substantial 3'-5' exonuclease activity are thermostable enzymes. A preferred embodiment of the invention is a composition comprising the *Taq* DNA polymerase (from *Thermus aquaticus*) and the *Pfu* DNA polymerase (from *Pyrococcus furiosus*).

Another aspect of the invention is to provide methods for synthesizing polynucleotides, typically DNA, using compositions comprising an enzyme that possesses substantial 3'-5' exonuclease activity and DNA polymerase with less 3'-5' exonuclease activity than the enzyme with substantial 3'-5' exonuclease activity.

10 Preferably, the DNA polymerase used in the provided methods is a DNA polymerase that substantially lacks 3'-5' exonuclease activity. The methods of synthesizing DNA (or other polynucleotides) provided comprise the step of mixing a composition containing (a) an enzyme possessing substantial 3'-5' exonuclease activity and (b) a DNA polymerase with less 3'-5' exonuclease activity than the enzyme with substantial

15 3'-5' exonuclease activity. Other reagents required for polynucleotide synthesis include nucleotide triphosphates (dNTPs), polynucleotide primers, a synthesis template, and the like.

Another aspect of the invention is to use the subject method of polynucleotide synthesis to carry out the synthesis step in a polymerase chain reaction experiment.

20 Yet another aspect of the invention is to provide kits for the synthesis of polynucleotides, wherein the kits comprise an enzyme that possesses substantial 3'-5' exonuclease activity and a DNA polymerase with less 3'-5' exonuclease activity than the enzyme with substantial 3'-5' exonuclease activity, preferably a DNA polymerase substantially lacking 3'-5' exonuclease activity. Preferably, the enzyme with substantial

25 3'-5' exonuclease activity is a DNA polymerase. The kits may also contain polynucleotide precursors, synthesis primers, synthesis templates, buffers, and the like.

DESCRIPTION OF SPECIFIC EMBODIMENTS

The subject invention provides novel composition for use in synthesizing polynucleotides, particularly DNA. The subject compositions comprise an enzyme that

30 possesses substantial 3'-5' exonuclease activity and a DNA polymerase with less 3'-5'

exonuclease activity than the enzyme with substantial 3'-5' exonuclease activity. In a preferred embodiment of the invention, the DNA polymerase in the compositions is a DNA polymerase that substantially lacks 3'-5' exonuclease activity. The enzyme that possesses substantial 3'-5' exonuclease activity is preferably a DNA polymerase. Prior
5 to the inventors' work, DNA synthesis in vitro was performed with a single purified DNA polymerase. In a variety of synthesis procedures, the subject compositions provide superior synthesis results, as compared with the synthesis results obtained with a single DNA polymerase with less 3'-5' exonuclease activity than the enzyme with 3'-5' exonuclease activity alone (including synthesis results obtained with DNA polymerases
10 that substantially lack 3'-5' exonuclease activity).

Although compositions comprising a DNA polymerase with less 3'-5' exonuclease activity than the enzyme possessing substantial 3'-5' exonuclease activity may produce superior results in a variety of synthesis experiments, the composition is especially useful in DNA synthesis when there exists one or more mismatched
15 nucleotide(s), particularly mismatches at the 3' end of one or more synthesis primer(s). In such situations, the results achieved, i.e., the amount of synthesis product produced, are significantly greater than the amount of synthesis product obtained using either a DNA polymerase with less 3'-5' exonuclease activity than the enzyme possessing substantial 3'-5' exonuclease activity or with a DNA polymerase possessing substantial
20 3'-5' exonuclease activity alone. Other advantages of the subject compositions and methods include increased synthesis product yield, increased transcription product length, and the synthesis of polynucleotides that can not be synthesized by a given DNA polymerase alone.

The enzyme possessing substantial 3'-5' exonuclease activity for use in the
25 subject compositions and methods may be any enzyme possessing substantial 3'-5' single- stranded DNA exonuclease activity. Enzymes possessing substantial 3'-5' exonuclease activity for use in the present compositions and methods may be isolated from natural sources or produced through recombinant DNA techniques. Enzymes that possess substantial 3'-5' exonuclease activity and their properties are described in detail
30 in, among other places, DNA Replication 2nd edition, Kornberg and Baker, supra and Enzymes, supra. Examples of enzymes that possess substantial 3'-5' exonuclease

activity include *E. coli* exonuclease I, *E. coli* exonuclease III, *E. coli* *recBCD* nuclease, mung bean nuclease, and the like. Preferred enzymes with substantial 3'-5' exonuclease activity for use in the subject compositions and methods are DNA polymerases that possess substantial 3'-5' exonuclease activity.

5 DNA polymerases that possess substantial 3'-5' exonuclease activity include the *Pfu* DNA polymerase, *E. coli* DNA polymerase I, Klenow fragment, T-4 polymerase, T-7 polymerase, *E. coli* DNA pol III, Ultima DNA Polymerase (Cetus), Vent DNA and Deep Vent DNA polymerases (New England Biolabs). When using the subject compositions in reaction mixtures that are exposed to elevated temperatures, e.g., during
10 the PCR technique, use of thermostable DNA polymerases is preferred. Examples of the thermostable DNA polymerases that possess substantial 3'-5' exonuclease activity include Vent DNA polymerase, Ultima DNA polymerase, Deep Vent DNA polymerase, and *Pfu* DNA polymerases. A particularly preferred DNA polymerase possessing 3'-5' exonuclease activity for use in subject composition is the *Pfu* DNA polymerase. The
15 *Pfu* DNA polymerase is commercially available from Stratagene (La Jolla, California). A detailed description of the *Pfu* DNA polymerase can be found, among other places in U.S. Patent Application serial number 07/803,627 filed December 2, 1991.

DNA polymerases and their properties are described in detail in, among other places, DNA Replication 2nd edition, Kornberg and Baker, W.H. Freeman, New York,
20 New York (1991). DNA polymerases with less 3'-5' exonuclease activity for use in the subject compositions and methods may be isolated from natural sources or produced through recombinant DNA techniques. DNA polymerases with less 3'-5' exonuclease activity than the 3'-5' exonuclease activity of the enzyme with substantial 3'-5' exonuclease activity, i.e., 3'-5' single-stranded exonuclease activity, include *Taq* DNA
25 polymerases and Sequenase™ (modified bacteriophage T7 DNA polymerase, available from U.S. Biochemical, Columbus, Ohio), and the like. Additionally, the person of average skill in the art having the benefit of this disclosure will recognize that exonuclease deficient polymerases such as Exo⁻ *Pfu* DNA polymerase, Vent® (exo⁻) DNA polymerase, Deep Vent® (exo⁻) DNA polymerase, and the like may be suitably
30 used in the subject compositions. *Taq* DNA polymerase, Sequenase™, Exo⁻ *Pfu* DNA

polymerase, Vent (exo⁻) DNA polymerase, and Deep Vent (exo⁻) DNA polymerase are all examples of DNA polymerases that substantially lack 3'-5' exonuclease activity.

When using the subject compositions in reaction mixtures that are exposed to elevated temperatures, e.g., during the PCR technique, use of thermostable DNA
5 polymerases is preferred. The subject composition may also be used with DNA polymerases that have not yet been isolated, provided that the DNA polymerases have less 3'-5' single-stranded DNA exonuclease activity than the enzyme with substantial 3'-5' exonuclease activity in the subject composition. Assays for both DNA polymerase activity and 3'-5' exonuclease activity can be found in DNA Replication 2nd Ed.,
10 Kornberg and Baker, supra, Enzymes, Dixon and Webb, Academic Press, San Diego, CA (1979), as well as other publications available to the person of ordinary skill in the art. A preferred DNA polymerase for use in the subject compositions and methods of the invention is the *Taq* DNA polymerase.

The term "substantially lacking 3'-5' exonuclease activity" when used in
15 reference to a DNA polymerase, refers to those DNA polymerases that have less 3'-5' exonuclease activity than the enzyme included in the subject composition that has substantial 3'-5' exonuclease activity.

The term "thermostable" when used with respect to an enzyme, is readily understood by a person of ordinary skill in the art. Typically, a "thermostable" enzyme
20 retains at least 50 percent of its specific activity after exposure to a temperature of 80°C for a period of 20 minutes.

The ratio of the DNA polymerase with less 3'-5' exonuclease activity than the enzyme possessing substantial 3'-5' exonuclease activity to the enzyme possessing substantial 3'-5' exonuclease activity in the subject composition may be varied with
25 respect to one another. The ratio of the DNA polymerase activity to 3'-5' exonuclease activity present in the subject composition employed in a given synthesis procedure may be readily optimized by performing a series of simple experiments in which the ratio of the DNA polymerase with less 3'-5' exonuclease activity than the enzyme with substantial 3'-5' exonuclease activity to the enzyme possessing substantial 3'-5'
30 exonuclease activity are systematically varied with respect to one another and the synthesis results compared.

The subject compositions may be used in various methods of synthesizing polynucleotides in essentially the same manner as the DNA polymerase present in the subject composition. Typically, synthesis of a polynucleotide requires a synthesis primer, a synthesis template, polynucleotide precursors for incorporation into the newly synthesized polynucleotide, (e.g. dATP, dCTP, dGTP, dTTP), and the like. Detailed methods for carrying out polynucleotide synthesis are well known to the person of ordinary skill in the art and can be found, for example, in Molecular Cloning second edition, Sambrook et al., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY (1989). The process of PCR employs a polynucleotide synthesis step in each cycle; this polynucleotide synthesis step may be achieved using the subject compositions.

The invention herein also contemplates a kit format which comprises a package unit having one or more containers of the subject composition and in some embodiments including containers of various reagents used for polynucleotide synthesis, including synthesis in PCR. The kit may also contain one or more of the following items: polymerization enzymes, polynucleotide precursors, primers, buffers, instructions, and controls. Kits may include containers of reagents mixed together in suitable proportions for performing the methods in accordance with the invention. Reagent containers preferably contain reagents in unit quantities that obviate measuring steps when performing the subject methods.

The following examples are offered for the purpose of illustrating, not limiting, the subject invention.

Background of Examples

CHARACTERISTICS OF *TAQ* AND *PFU* DNA POLYMERASES

Thermus aquaticus DNA Polymerase

Thermus aquaticus (*Taq*) DNA polymerase is a 94-kDa protein which does not have an inherent 3' to 5' exonuclease activity (Tindall, K.R., and T.A. Kunkel. 1988. Fidelity of DNA synthesis by the *Thermus aquaticus* DNA polymerase. *Biochemistry* 27:6008-6013). 3' to 5' exonuclease activity enables a polymerase to proofread and is

therefore associated with fidelity of an enzyme. The estimated error rate of *Taq* varies from 2×10^{-4} mutations per nucleotide per cycle during PCR (Saiki, R.K., D.H. Gelfand, S. Stoffel, S.J. Scharf, R. Higuchi, G.T. Horn, K.B. Mullis, and H.A. Erlich. Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase. 5 1988. *Science* 239:487-491) to 2×10^{-5} for nucleotide substitution errors in a single round of DNA synthesis of the *lacZ α* gene (Eckert, K.A. and T.A. Kunkel. High fidelity DNA synthesis by the *Thermus aquaticus* DNA polymerase. 1990. *Nucleic Acids Res.* 18:3739-3744). The error rate of *Taq* DNA polymerase is important in polymerization because it reflects the ability of the polymerase to extend from a mismatched 10 primer:template. *Taq* DNA polymerase has been shown to extend significantly less efficiently from a mismatched primer: template than from a correctly based paired primer:template (Innis, M.A., K.B. Myambo, D.H. Gelfand and M.A.D. Brow. DNA sequencing with *Thermus aquaticus* DNA polymerase and direct sequencing of polymerase chain reaction-amplification of DNA. 1988. *Proc. Natl. Acad. Sci. USA.* 15 85:9436-9440 and Kwok, S., D.E. Kellogg, D. Spasic, L. Goda, C. Levenson, and J.J. Sninsky. Effects of primer-template mismatches on the polymerase chain reaction: Human immunodeficiency virus type 1 model studies. 1990. *Nucleic Acids Res.* 18:999-1005).

Taq DNA polymerase is highly processive at an extension rate of >60 nucleotides 20 per second at 70°C on M13 phage DNA when using a GC-rich 30 mer as a primer (Innis, et al. 1988). The *Taq* genome is 66.8% GC (Munster, M.J., A.P. Munster, J.R. Woodrow, and R.J. Sharp. Isolation and preliminary taxonomic studies of *Thermus* strains isolated from Yellowstone National Park, USA. 1986. *J. of Gen. Microbiol.* 132:1677-1683).

25 *Pyrococcus furiosus* DNA polymerase

Pyrococcus furiosus (*Pfu*) DNA polymerase is a 91-kDa protein which has an inherent 3' to 5' exonuclease activity. This proofreading activity allows *Pfu* to extend from mismatched primer:templates by first removing the mismatched base(s) followed by polymerization and results in an error rate of 1.6×10^{-6} mutations per nucleotide per 30 cycle in PCR reactions. The error rate of *Pfu* DNA polymerase is thus tenfold lower

than that of *Taq* DNA polymerase and results in higher fidelity (Lundberg, K.S., D.D. Shoemaker, M.W.W. Adams, J.M. Short, J.A. Sorge, and E.J. Mathur. High-fidelity amplification using a thermostable DNA polymerase isolated from *Pyrococcus furiosus*. 1991. *Gene* 108:1-6). The processivity of *Pfu* DNA polymerase is 10-15 nucleotides per second and its genome is 38% GC.

TEMPLATES

cDNA templates

cDNAs from 2 sources, hybridoma and PBLs (peripheral blood lymphocytes), were chosen as templates in these experiments. Hybridoma cDNA from human anti-tetanus toxoid 9F12 (ATCC, HM-8177) and mouse anti-human fibronectin CG7C7 (ATCC, HB-126) express only one immunoglobulin heavy and light chain and therefore would contain a homogeneous population of heavy and light chain cDNAs. The 9F12 cDNA had amplified efficiently in previous experiments when using primers AB-61 or MK-205 with AB-76 (Fd) or MK-39 (VH), AB-25 and AB-94 (light chain[LC]), and MK-94 and AB-76 (CH1). Based on nucleotide sequence, 9F12 is a human IgG1 from the VHIII family with a *kappa* light chain. The SA-13 cDNA had amplified efficiently in previous experiments when using primers AB-19 with AB-41 (Fd) and AB-25 and AB-26 (LC). PBL cDNA expresses immunoglobulin heavy and light chains from all of the human heavy and light chain families (Kabat, T.T. Wu, H. Bilofsky, M. Reid-Milner, and H. Perry, eds. Sequences of Proteins of Immunological Interest, 1987, U.S. Public Health Service, Washington, D.C.) and therefore would contain a heterogenous population of heavy and light chain cDNAs. This cDNA had not amplified efficiently with primer AB-61 or MK-205 with AB-76 (Fd) or MK-39 (VH) but had amplified efficiency with AB-25 and AB-94 (LC) and MK-94 and AB-76 (CH1) (Table 13).

25 DNA templates

Nine different DNA templates were also used in these experiments. The genomic DNAs were isolated from human, Epstein Barr virus, *Escherichia coli*, and transgenic and nontransgenic mouse. Plasmid DNAs were pBluescript II and pBluescript containing the light chain and Fd of an anti-tetanus toxoid immunoglobulin

(Mullinax R.L., E.A. Gross, J.R. Amberg, B.N. Hay, H.H. Hogrefe, M.M. Kubitz, A. Greener, M. Alting-Mees, D. Ardourel, J.M. Short, J.A. Sorge, and B. Shopes. 1990. Identification of human antibody fragment clones specific for tetanus toxoid in a bacteriophage lambda immunoexpression library. *Proc. Natl. Acad. Sci. USA* 87:8095-8099).

PRIMER DESIGN

The ability of an oligonucleotide to act as a primer in DNA synthesis is dependent on several factors: the kinetics of association and dissociation of the primer:template duplexes under the annealing and extension conditions, the effects of mismatched bases and their location on duplex stability, and the efficiency with which the polymerase can recognize and extend from a mismatched duplex. In general, single base pair mismatches at or near the terminal 3' base of a primer are known to affect the ability of the polymerase to bind and extend from the primer:template and therefore should have a significant effect on the efficiency of the priming reaction.

In particular, *Taq* DNA polymerase requires that 3 to 5 bases at the 3' end of the primer base pair exactly in order for polymerization to occur. The effect of other mismatches on the efficiency of polymerization is dependent on the number of mismatches and where they occur in the primer. This presents a problem when the exact template sequence is not known such as when the nucleotide sequence of the template is derived from amino acid sequence due to the redundancy of the amino acid code and when designing primers for templates of families of genes which are heterogeneous.

Four oligonucleotide primers designed to specifically prime the first constant region of human heavy chain immunoglobulin genes (VH) were designed based on the available nucleotide and amino acid sequences with the problems above in mind (Mullinax, et al., 1990). Because experimental results indicated poor priming and/or amplification efficiency with PBL templates with *Taq* DNA polymerase, we wanted to investigate how this efficiency could be improved.

One of the human heavy chain first constant region primers, AB-61 (Table 15) was chosen for examination. AB-61 has a dGTP as the 3' base and would require a

dCTP in the corresponding position in the template in order for efficient priming to occur when *Taq* DNA polymerase was used for primer extension due to its lack of 3' to 5' exonuclease activity (Kwok, et al. 1990, supra). However, *Pfu* DNA polymerase does have 3' to 5' exonuclease activity and would remove any mismatched base(s) from the 3' end of the primer and would therefore be able to extend (Lundberg, et al. 1991, supra). Therefore it was of interest to investigate the effect of using *Pfu* DNA polymerase alone and in combination with *Taq* DNA polymerase in primer extension reactions using cDNA from hybridoma cell lines (9F12 and CG7C7) and from human PBLs as the template under various experimental conditions.

10 Kwok, et al. (1990) demonstrated that primer extension efficiency when using *Taq* DNA polymerase is independent of the dNTP in the template when a dTTP is the 3' base in the primer. Therefore the effect of the addition of one or more dTTPs in various positions at the 3' end of the primer AB-61 (Table 13) was also investigated.

BUFFER COMPARISONS

15 Buffer conditions have been shown to effect the processivity, activity and fidelity of polymerases. In particular, the processivity and/or activity of *Taq* DNA polymerase are known to be affected by KCl, MgCl₂, (NH₄)₂SO₄, and NaCl concentrations. The fidelity of *Taq* DNA polymerase is also affected by the concentration of MgCl₂ relative to the total concentration of dNTPs (Eckert, et al. 1990, supra) and dNTP and MnCl₂ concentrations (Leung, D.W., E. Chen, and D.V. Goeddel. 1989). A method for random mutagenesis of a defined DNA segment using a modified polymerase chain reaction. *Technique*. 1:11-15).

Table 17 lists the buffer components and their concentrations for the 10x *Taq* DNA polymerase and *Pfu* V25, #1, and #3 buffers used in these experiments.

25 DIFFERENT RATIOS OF *TAQ* AND *PFU* DNA POLYMERASES

Taq DNA polymerase is unable to correct nucleotide misincorporations made during polymerization due to its lack of 3' to 5' exonuclease activity. In general, this would result in the inability of *Taq* to extend from a newly polymerized strand annealed to a template when an incorrect nucleotide has been inserted. *Pfu* DNA polymerase has

an inherent 3' to 5' exonuclease activity and would be able to remove the incorrectly inserted nucleotide and then extend from the correctly base paired primer:template. The ratio of the two polymerases may be critical for optimal efficiency of this process. We therefore compared several ratios of *Taq*:*Pfu* DNA polymerases to determine the effect
5 on DNA synthesis from 3' matched and mis-matched primers.

In addition, *Pfu* DNA polymerase has been shown to degrade unannealed primers by its 3' to 5' exonuclease activity. These degraded primers would not be available in subsequent rounds of DNA amplification and would therefore effect the efficiency of the PCR reaction. It may therefore be desirable to have a low concentration of *Pfu* DNA
10 polymerase relative to *Taq* DNA polymerase to decrease this effect.

EXAMPLE 1

PRIMER EXTENSION WITH *TAQ* OR *PFU* DNA POLYMERASE IN SEPARATE REACTIONS

These experiments demonstrate the relative ability of *Taq* or *Pfu* DNA
15 polymerase to PCR amplify hybridoma and PBL templates under various conditions. *Taq* DNA polymerase resulted in either the presence of a PCR product or an increase in the amount of PCR product when compared to *Pfu* DNA polymerase when amplifying hybridoma and PBL templates. In addition, the dNTP and not the MgCl₂ concentration affected the amount of LC product generated.

20 *Taq* and *Pfu* DNA polymerases with CG7C7 hybridoma template

Taq and *Pfu* DNA polymerases were compared for their ability to amplify the LC, CH1, and Fd regions of a mouse anti-human fibronectin antibody (CG7C7, ATCC HB-126). Total RNA was isolated from CG7C7 hybridoma cells using an RNA isolation kit (Stratagene). Five µg of total RNA was converted to cDNA in a first
25 strand synthesis reaction using an oligo-dT primer for the light chain and AB-41 for the heavy chain (Table 15). mRNA was annealed to the first strand primer at 65°C for 5 minutes followed by cooling at room temperature for 30 minutes. First strand reactions were performed in 1x first strand buffer [1x first strand buffer is 75 mM KCl; 50 mM tris-Cl, pH 8.3; 10 mM dithiothreitol; 3 mM MgCl₂; 1 Unit RNase Block II

(Stratagene)], 375 μ M each dNTP and 20 Units Moloney-Murine Leukemia Virus Reverse Transcriptase (M-MLVRT) (Stratagene)] and incubated at 37°C for 1 hour and then 42°C for 30 minutes.

PCR primers used to amplify the LC were AB-25 and AB-26, CH1 were MK-501 and AB-41, Fd were AB-41 and AB-19, and the polylinker region of pBluescript were T3 and T7 (Table 14). PCR reactions with *Taq* DNA polymerase were at a primer concentration of 0.2 μ M of each 5' and 3' primer in 1x *Taq* buffer (Table 17) with 200 μ M each dNTP and 2.5 units *Taq* DNA polymerase (Stratagene; La Jolla, California) using 1/10 of cDNA prepared in the first strand reaction as the template. Samples were denatured at 99°C for 5 minutes and annealed at 54°C for 5 minutes followed by PCR amplification at 72°C for 3 minutes, 93°C for 1.5 minutes and 54°C for 2 minutes for 30 cycles.

PCR reactions with *Pfu* DNA polymerase were performed under the same conditions but with 1x V25 buffer instead of *Taq* buffer.

Twenty μ l of the 100 μ l reaction was separated on an agarose gel by electrophoresis and visualized by staining with ethidium bromide. Results are indicated by the relative amount of appropriately sized PCR product and all given in Table 1.

Table 1

Taq and *Pfu* DNA polymerases with CG7C7 template

Product	Primers	<i>Taq</i> buffer	V25 buffer
		<i>Taq</i>	<i>Pfu</i>
Fd	AB-19/AB-41	2+	+/-
CH1	MK-501/AB-41	2+	+
LC	AB-25/AB-26	+	-
polylinker	T3/T7	+	-

The relative amounts of PCR product are indicated as a range of no product (-) to the most product (5+).

Results from this experiment indicate that only *Taq* DNA polymerase produced an appropriately sized PCR product with all of the primer pairs used. *Pfu* DNA polymerase produced either less or no product when compared to *Taq* DNA polymerase with all of the primer pairs.

- 5 The CH1 primers were designed for amplification of constant regions of the antibody heavy chain and would be expected to base pair match perfectly with their template. The T3 and T7 primers also base pair match perfectly with the pBluescript template.

Taq and *Pfu* DNA polymerases with PBL template

- 10 *Taq* DNA polymerase was used to amplify the LC (both *kappa* and *lambda*), CH1, CH2/CH3, and Fd regions of human PBL immunoglobulins. The $MgCl_2$ and dNTP concentrations were varied to try to increase the amount of PCR product generated. Total RNA was isolated from human PBLs using an RNA isolation kit (Stratagene). Five μg of total RNA was converted to cDNA in a first strand synthesis
15 reaction using an oligo-dT primer for the LC, and MK-25 for the heavy chain. mRNA was annealed to the first strand primer at 65°C for 5 minutes followed by cooling at room temperature for 30 minutes. First strand reactions were performed in 1x first strand buffer [1x first strand buffer is 75 mM KCl; 50 mM tris-Cl, pH 8.3; 10 mM dithiothreitol; 3 mM $MgCl_2$; 1 Unit RNase Block II (Stratagene)], 375 μM each dNTP
20 and 20 Units Moloney-Murine Leukemia Virus Reverse Transcriptase (M-MLVRT) (Stratagene)] and incubated at 42°C for 1 hour.

- PCR primers used to amplify the *kappa* LC were AB-25 and AB-26, *lambda* LC were AB-92 and AB-28, CH2/CH3 were MK-25 and MK-26, Fd were AB-52 with AB-61, AB-62, AB-63, or AB-64 (Table 18). PCR reactions were at a primer concentration
25 of 0.2 μM of each 5' and 3' primer in 1x *Taq* buffer (Table 17) with 2.5 units *Taq* DNA polymerase using 1/10 of cDNA prepared in the first strand reaction as the template. The *kappa* LC reaction was 2.0 mM $MgCl_2$ with 237.5 μM dNTPs, the *lambda* LC reaction was 1.8 mM $MgCl_2$ at 137.5 μM or 237.5 μM dNTPs, the Fd reactions were 1.9 mM $MgCl_2$ with 187.5 μM dNTPs, and the CH2/CH3 reactions were
30 at 1.5 mM $MgCl_2$ with 137.5 μM dNTPs. Samples were denatured at 94°C for 5

minutes and annealed at 54°C for 5 minutes followed by PCR amplification at 72°C for 2.5 minutes, 93°C for 1 minute and 54°C for 1.5 minutes for 40 cycles. Samples were analyzed as described above. Results are indicated by the relative amount of appropriately sized PCR product and are given in Table 2.

5

Table 2

Taq and *Pfu* DNA polymerases with PBL template

PBL template						
		1.9 mM MgCl ₂	1.8 mM MgCl ₂		2.0 mM MgCl ₂	
primers	product	187.5 μM dNTP	137.5 μM dNTP	237.5 μM dNTP	137.5 μM dNTP	237.5 μM dNTP
10	AB-61/AB-52	-				
	AB-62/AB-52	-				
	AB-63/AB-52	-				
	AB-64/AB-52	-				
	MK-25/MK-26	-	-	-	-	-
15	AB-25/AB-26					4+
	AB-92/AB-28		+	4+	+	4+

Only the *kappa* and *lambda* LC reactions produced a specific PCR product. The 1.8 and 2.0 mM MgCl₂ with 137.5 μM dNTP *lambda* LC reactions produced only a very small amount of PCR product while the 1.8 and 2.0 mM MgCl₂ with 237.5 μM dNTPs produced a large amount of PCR product. This indicates that the amount of PCR product in this experiment is related to the dNTP and not the MgCl₂ concentration. No PCR product was generated with the Fd or CH2/CH3 primers under the conditions used.

20

EXAMPLE 2

PRIMER EXTENSION REACTIONS WITH 3' MISMATCHED PRIMERS

These experiments investigated the ability of *Taq* and *Pfu* DNA polymerases both together and in separate reactions to extend from primers which contain one or two 3' mismatches. The first experiment demonstrates that *Taq* DNA polymerase can only extend from a primer which matches at the 3' end under the conditions used (2.1 and 6.1 mM MgCl₂). The next experiment demonstrates that *Taq* and *Pfu* DNA polymerases used in the same reaction will extend from all the primers with 3' mismatches that were used from both hybridoma and PBL templates while neither polymerase alone was able to extend from all primers. The combination of both polymerases also resulted in more product in some of the samples.

This series of experiments suggest that *Taq* in *Taq* buffer will extend from a primer that is perfectly matched at the 3' end, in V25 buffer will extend from a primer that has one T which creates a mismatch at the 3' end of a primer, and in V25 buffer will not extend from a primer that has two Ts which create two mismatches at the 3' end of a primer. *Taq* and *Pfu* DNA polymerases in V25 buffer will extend from a primer that has two Ts which create a mismatch at the 3' end of a primer.

It was also speculated that *Taq* and *Pfu* DNA polymerases may complement each other in the reaction by polymerizing through A:T or G:C rich regions of a template where one enzyme could not polymerize well through both types of regions. The *Pfu* genome is 38% GC while the *Taq* genome is 66.8% GC.

Taq DNA polymerase with 9F12 template

The ability of *Taq* DNA polymerase to extend from primers with one or more mismatches at the 3' end was investigated. Nucleotide sequences of the 5' primers based on the AB-61 primer and used to amplify 9F12 cDNA are given in Table 12. The 3' primer in reactions which amplified the Fd portion of the human heavy chain was AB-76. The 3' primer in reactions which amplified the VH portion of the human heavy chain was MK-39. The light chain 5' VL primer was AB-25 and the 3' CL primer was AB-94.

9F12 cDNA template was generated by isolating total RNA from the hybridoma cells using an RNA isolation kit (Stratagene). mRNA is converted to cDNA in a first strand synthesis reaction using an oligo-dT primer for the light chain and AB-76 for the heavy chain. The first strand reactions was performed as described above except 200 units of Superscript (BRL; Gaithersburg, MD)] was substituted for M-MLVRT and the reactions were incubated at 42°C for 1 hour.

PCR reactions were at a primer concentration of 0.2 μ M of each 5' and 3' primer in 1x *Taq* buffer (Table 17) with either 2.1 or 6.1 mM $MgCl_2$, 175 μ M each dNTP and 2.5 units *Taq* DNA polymerase using 1/10 of the cDNA prepared in the first strand reaction as the template. Samples were denatured at 95°C for 5 minutes and annealed at 54°C for 5 minutes followed by PCR amplification at 72°C for 3 minutes, 93°C for 1.5 minutes and 54°C for 2.5 minutes for 40 cycles. Samples were analyzed as described above and the results are given in Table 3.

Table 3

Taq DNA polymerase with 9F12 template

primers	product	<i>Taq</i> in <i>Taq</i> buffer	
		2.1 mM $MgCl_2$	6.1 mM $MgCl_2$
AB-61/AB-76	Fd	2+	-
AB-714/AB-76	Fd	-	-
AB-715/AB-76	Fd	-	-
AB-716/AB-76	Fd	-	-
AB-717/AB-76	Fd	-	-
AB-61/MK-39	VH	2+	+

PCR products of the appropriate size were generated only when AB-61 was used as the 5' primer. None of the 3' mismatched primers generated a PCR product of the appropriate size although many inappropriately sized products were made. Fd and VH products were generated in the reaction containing 2.1 mM $MgCl_2$ while only the VH was produced in the reaction containing 6.1 mM $MgCl_2$.

These results suggested that *Taq* DNA polymerase was not able to extend from 3' mismatched primers under the conditions used and that increasing the MgCl_2 concentration did not result in either an increase in PCR product, the ability to extend from 3' mismatched primers, or generation of PCR products not made with 2.1 mM MgCl_2 .

Taq and *Pfu* DNA polymerases with 9F12 and PBL templates

The next experiment investigated the effect of using *Pfu* and *Taq* DNA polymerases in the same PCR reaction to extend from primers with 3' matches and mismatches. The same primers were used (MK-205 which has the same 21 bp on the 3' end as AB-61 was substituted for AB-61) as described above to amplify Fd, VH, CH1, and LC from PBL and 9F12 cDNAs. PCR reactions were performed in 1x V25 buffer (Table 17) with 200 μM each dNTP and 2.5 units of both *Taq* and *Pfu* DNA polymerases or with *Pfu* DNA polymerase alone using cDNA generated as described above from 9F12 & PBL RNA as the template. Samples were denatured at 94°C for 5 minutes and annealed at 47°C for 5 minutes followed by PCR amplification at 71°C for 3 minutes, 92°C for 1 minute and 47°C for 2.5 minutes for 5 cycles and 71°C for 3 minutes, 92°C for 1 minute and 51°C for 2.5 minutes for 35 cycles. The lower annealing temperatures were used to try to improve primer:template annealing when mismatches occurred. Samples were analyzed as described above and the results are given in Tables 4 and 5.

Table 4

Taq and *Pfu* DNA polymerases with 9F12 and PBL templates

V25 buffer				
	9F12 template		PBL template	
	<i>Pfu/Taq</i>			<i>Pfu</i>
primers	Fd	VH	Fd	VH
AB-61/AB-76	5+	5+	+	+/-
AB-714/AB76	5+	5+	2+	+/-
AB-715/AB76	2+	5+	+/-	+/-
AB-716/AB76	5+	5+	2+	+/-
AB-717/AB76	5+	5+	+	+/-

Table 5

		9F12 templates		PBL templates	
		<i>Pfu/Taq</i>			<i>Pfu</i>
primers	product	Fd	VH	Fd	VH
MK-94/AB-76	CH1	5+		+/-	+/-
AB-25/AB-94	LC	+/-		+/-	+/-

An unexpected result in this experiment was that more amplification product was generated when *Taq* and *Pfu* DNA polymerases were used in the same PCR reaction in V25 buffer with both 9F12 and PBL cDNA as the template. Numerous previous experiments using identical first strand synthesis and PCR conditions with *Taq* DNA polymerase had resulted in only a very small amount of Fd product generated from the same PBL mRNA. A very small amount of VH and CH1 products were generated using *Pfu* DNA polymerase alone in V25 buffer with PBL cDNA as a template.

Significant amounts of both Fd and VH PCR products were generated with 9F12 cDNA as a template with all of the 5' primers, including the 3' mismatched primers (AB-714 to AB-717), when both *Taq* and *Pfu* DNA polymerases were used. This

contrasted with the previous experiment when *Taq* DNA polymerase was not able to extend from the 3' mismatched primers (AB-714 through AB-717) under the conditions used. These results suggested that *Pfu* DNA polymerase can remove 1-2 mismatched bases from the 3' end of the primer. This would enable either *Pfu* or *Taq* DNA polymerase to extend from the perfectly base paired primer:template.

Taq and *Pfu* DNA polymerases with 9F12 and PBL templates

The above experiment was repeated to verify the results. The same primers were used to amplify Fd, CH1, and LC using PBL and 9F12 cDNAs as templates. PCR reactions were performed in V25 buffer (Table 17) with 200 μ M each dNTP and 2.5 units of both *Taq* and *Pfu* DNA polymerases either together in the same reaction and or in separate reactions. PCR conditions were the same as described above and the results are given in Table 5.

Table 6

Taq and *Pfu* DNA Polymerases with 9F12 and PBL Templates

		V25 buffer						
		9F12 template			PBL template			
15	primers	product	Taq	Pfu	Pfu/Taq	Taq	Pfu	Pfu/Taq
	AB-61/AB-76	Fd	-	-	+	-	+	-
	AB-714/AB-76	Fd	3+	-	4+	+	-	3+
	AB-715/AB-76	Fd	-	-	2+	-	-	+
	AB-716/AB-76	Fd	4+	-	4+	3+	+	+
20	AB-717/AB-76	Fd	2+	-	4+	+	-	3+
	MK94/AB-76	CH1	4+	4+	4+	3+	-	-
	AB-25/AB-94	LC	2+	-	-	+	-	-

PCR products generated with *Pfu* were Fd with MK-205 from PBL template and CH1 from 9F12 template. PCR products generated with *Taq* were Fd with AB-714, AB-716, AB-717, CH1, and LC with PBL template and Fd with AB-714, AB-716, AB-

717, CH1 and LC with 9F12 template. PCR products generated with *Pfu* and *Taq* were Fd with MK-205, AB-714, AB-717 and a very small amount with AB-715 and AB-716 from PBL template. PCR products generated with *Pfu* and *Taq* were Fd with AB-714, AB-715, AB-716, AB-717 and CH1 from 9F12 template.

5 The amount of PCR product varied, however, in general more product was generated with the 9F12 template than with the PBL template. This may be due to the heterogeneity of the PBL template when compared to the homogeneity of the 9F12 hybridoma template. When a homogeneous template is amplified and the strand is not completed, it may anneal to its template in a subsequent round of amplification and be
10 extended to full length. When a heterogeneous template is amplified and the strand is not complete, the chances of it annealing to its original template in a subsequent round of amplification will be related to the heterogeneity of the templates present but will be less than that of a homogeneous template. This may help explain why homogeneous templates produce more PCR product than heterogenous templates.

15 In this experiment *Taq* DNA polymerase was able to extend from the 3' mismatched primers which contain only a single mismatched base (AB-714, AB-716, and AB-717) but not one that has two mismatched bases (AB-715) with both the PBL and 9F12 cDNA templates. In a previous experiment, *Taq* DNA polymerase was not able to do this, however, these results are consistent with the results of Kwok, et al.
20 (1990, supra). Both AB-715 and AB-717 contain 2 dTTPs at the 3' end of the primer but in different positions. AB-715 replaces the last two dGTPs on the 3' end and AB-717 replaces the last dGTP and adds a dTTP to the 3' end. Because the corresponding base in the template is not known, the 3' dTTP in AB-717 may not create a mismatch with the template.

25 The V25 buffer used in this experiment had been made incorrectly and was 5 mM KCl instead of 10 mM KCl. KCl concentration has been shown to effect processivity and/or activity of *Taq*. This was corrected for all future experiments.

EXAMPLE 3

EFFECT OF DIFFERENT RATIOS OF *TAQ* AND *PFU* DNA POLYMERASES ON EXTENSION FROM 3' MISMATCHED PRIMERS

This experiment investigated different ratios of *Taq* and *Pfu* DNA polymerases and template concentrations when amplifying from perfectly matched and 3' mismatched primers. Plasmid DNA which encoded an anti-tetanus toxoid immunoglobulin fragment (*kappa* light chain and Fd portion of the heavy chain) was used as the template (Mullinax et al. 1990, *supra*). Although optimal polymerase ratios and template concentrations were not identified in these experiments, additional experimentation would need to be done before concluding that they did not have an effect.

EFFECT OF *PFU* DNA POLYMERASE RATIO ON EXTENSION FROM 3' MISMATCHED PRIMERS

Five different ratios of *Taq* and *Pfu* DNA polymerases were used in PCR reactions with a combined total of 2.5 units per reaction. The ratios were 9:1, 7:3, 5:5, 3:7, and 1:9 of *Taq:Pfu*. The Fd primers were AB-61, AB-715, and AB-717 in V25 buffer. Anti-tetanus toxoid plasmid DNA encoding a *kappa* LC and Fd was used as the template. Samples were denatured at 95°C for 7 minutes and annealed at 40°C for 7-10 minutes followed by PCR amplification at 72°C for 2 minutes, 95°C for 1 minute and 50°C for 2 minutes for 30 cycles. Samples were analyzed as described above and results are given below.

Table 7

EFFECT OF DIFFERENT RATIOS OF *TAQ* AND *PFU* DNA POLYMERASES ON EXTENSION FROM 3' MISMATCHED PRIMERS

primers	product	ratio of <i>Taq:Pfu</i> DNA polymerases						
		10:0	9:1	7:3	5:5	3:7	1:9	0:10
AB-61/AB-76	Fd	4+	5+	5+	5+	5+	4+	4+
AB-715/AB-76	Fd	-	5+	5+	5+	5+	2+	5+
AB-717/AB-76	Fd	2+	5+	5+	5+	5+	5+	5+

All PCR reactions generated a significant amount of PCR product with little variation except the reactions with AB-715 and AB-717 with *Taq* DNA polymerase alone and the reaction with *Taq:Pfu* at 1:9 with AB-715. All of the reactions which combine both *Taq* and *Pfu* DNA polymerases or contain *Pfu* alone produced a significant amount of product. *Taq* DNA polymerase alone not would be expected to extend efficiently from the 3' mismatched primers.

Template concentration can affect the amplification efficiency and may explain there is little difference in the amount of PCR product in the different samples when the ratio of DNA polymerases is varied. In the next experiment, three different template concentrations were used to try to determine the effect of template concentration.

EFFECT OF TEMPLATE CONCENTRATION

Template concentrations were 100, 50, and 10 nanograms per reaction with either 2.5 units of *Taq* or *Pfu* DNA polymerase in the reaction in V25 buffer. The Fd primers were AB-61, AB-715, and AB-717 in V25 buffer. Samples were denatured at 95°C for 7 minutes and annealed at 40°C for 7-10 minutes followed by PCR amplification at 72°C for 2 minutes, 95°C for 1 minute and 50°C for 2 minutes for 30 cycles. Samples were analyzed as described above and results are given in Table 8.

Table 8
EFFECT OF TEMPLATE CONCENTRATION

		template concentration					
		100 ng		50 ng		10 ng	
		<i>Taq</i>	<i>Pfu</i>	<i>Taq</i>	<i>Pfu</i>	<i>Taq</i>	<i>Pfu</i>
primers	product						
AB-61/AB-76	Fd	5+	5+	5+	5+	5+	5+
AB-715/AB-76	Fd	5+	5+	5+	5+	5+	5+
AB-717/AB-76	Fd	5+	5+	5+	5+	5+	2+

Varying the template concentration did not seem to have an effect on the amount of PCR template generated except in the 10 ng template sample with *Pfu* DNA

polymerase alone with AB-717. The results seen previously with AB-715 where there was no amplification with *Taq* DNA polymerase alone was not reproduced and the experimenter indicated that an error could have been made. The experiment with AB-715 alone was repeated.

- 5 This experiment repeated the experiment described above using just the AB-715 primer under the same conditions. Samples were analyzed and described above and results are given in Table 9.

Table 9
EFFECT OF TEMPLATE CONCENTRATION

		template concentration						
		100 ng		50 ng		10 ng		
10	primer	product	<i>Taq</i>	<i>Pfu</i>	<i>Taq</i>	<i>Pfu</i>	<i>Taq</i>	<i>Pfu</i>
	AB-715/AB-76	Fd	4+	3+	3+	2+	1+	5+

- The amount of PCR product generated correlated with template concentration in the reactions with *Taq* DNA polymerase alone and may indicate that the template concentration affects amplification efficiency from mismatched primers. No consistent
15 effect could be correlated with *Pfu* DNA polymerase.

EXAMPLE 4

EFFECT OF ANNEALING TEMPERATURE ON EXTENSION FROM 3' MISMATCHED PRIMERS

- The next experiment compared *Taq* and *Taq* with *Pfu* in *Taq* and V25 buffers
20 with mismatched primers at different annealing temperatures. This experiment demonstrates that more PCR product is generated from a perfectly matched primer at a lower annealing temperature than at a higher temperature. No product was produced with the primer with 2 mismatches under any of the conditions used.

Effect of annealing temperatures of extension from 3' matched and mismatched primers

- Taq* and *Taq* with *Pfu* in *Taq* and V25 buffers with mismatched primers were extended at different annealing temperatures. The Fd primers were AB-61 and AB-715. cDNA templates were prepared from PBLs and 9F12. Samples were denatured at 95°C for 5 minutes and annealed at either 48°C or 52°C for 5 minutes followed by PCR amplification at 71°C for 3 minutes, 92°C for 1 minute and 48°C or 52°C for 2.5 minutes for 5 cycles and 71°C for 3 minutes, 92°C for 1 minute and 54°C for 2.5 minutes for 40 cycles. The lower annealing temperatures were used to determine the effect the lower temperature had on primer:template annealing when mismatches occurred.
- 10 Samples were analyzed as previously described and results are given in Table 10.

Table 10

Effect of Annealing Temperatures on Extension From
3' Matched and Mismatched Primers

		annealing at 48°C (x5 cycles) and 52°C (x35 cycles)							
		9F12 template				PBL template			
		<i>Taq</i> buffer		V25 buffer		<i>Taq</i> buffer		V25 buffer	
primers	product	<i>Taq</i>	<i>Pfu</i> / <i>Taq</i>	<i>Taq</i>	<i>Pfu</i> / <i>Taq</i>	<i>Taq</i>	<i>Pfu</i> / <i>Taq</i>	<i>Taq</i>	<i>Pfu</i> / <i>Taq</i>
15 AB-61/AB-76	Fd	4+	4+	4+	4+	+/-	+	-	+/-
AB-715/AB-76	Fd	-	-	-	-	-	-	-	-

		annealing at 54°C (x40 cycles)							
		9F12 template				PBL template			
		<i>Taq</i> buffer		V25 buffer		<i>Taq</i> buffer		V25 buffer	
primers	product	<i>Taq</i>	<i>Pfu</i> / <i>Taq</i>	<i>Taq</i>	<i>Pfu</i> / <i>Taq</i>	<i>Taq</i>	<i>Pfu</i> / <i>Taq</i>	<i>Taq</i>	<i>Pfu</i> / <i>Taq</i>
AB-61/AB-76	Fd	4+	4+	2+	+	-	-	-	-
AB-715/AB-76	Fd	-	-	-	-	-	-	-	-

PCR products generated with *Pfu* and *Taq* in *Taq* or V25 buffers were a very small amount of Fd using AB-61 with the PBL template at the lower and not the higher annealing temperature. PCR products generated with *Taq* with and without *Pfu* in *Taq* or V25 buffer using AB-61 with the 9F12 template resulted in more product at the lower rather than the higher annealing temperature. No PCR products were generated with the AB-715 primer in any samples.

Results indicated that none of the polymerases or buffer combinations tested extended from the AB-715 primer. AB-61 and AB-715 differ by the deletion of two dGTPs and the addition of two dTTPs at the 3' end (Table 13). The lower annealing temperatures did produce either the presence of or an increase in the amount of PCR product generated.

EXAMPLE 5

PCR REACTIONS USING PRIMERS WITHOUT 3' MISMATCHES

The object of the experiments with the 3' mismatched primers was to determine PCR conditions would result in a sufficient amount of high fidelity PCR product to enable cloning of the encoded immunoglobulin fragments. Therefore, the original PCR primers designed to amplify all human heavy chain genes were now used in the PCR reactions with *Taq* and *Pfu* DNA polymerases separately and in the same reaction. Results indicate that there was no significant difference in the amount of PCR product generated when either *Taq* or *Taq* and *Pfu* DNA polymerases were used in these experiments.

Taq and *Pfu* DNA polymerases with 9F12 and PBL templates

The first strand synthesis and PCR reactions were performed as described above under PCR REACTIONS WITH 3' MISMATCHED PRIMERS - *Taq* and *Pfu* DNA polymerases with 9F12 and PBL templates with the following change. AB-61, AB-62, AB-63, and AB-64 (Table 18) were used as the 5' VH primers. Samples were analyzed as described above and results are given in Table 11.

Table 11

Taq and *Pfu* DNA Polymerases With 9F12 and PBL Templates

		V25 buffer					
		9F12 template			PBL template		
primers	product	<i>Taq</i>	<i>Pfu</i>	<i>Pfu/Taq</i>	<i>Taq</i>	<i>Pfu</i>	<i>Pfu/Taq</i>
AB-61/AB-76	Fd	4+	-	-	4+	+/-	4+
AB-62/AB-76	Fd	4+	-	4+	4+	+/-	4+
AB-63/AB-76	Fd	4+	+	4+	+/-	-	-
AB-64/AB-76	Fd	4+	-	4+	2+	-	2+
MK-94/AB-76	CH1	4+	3+	4+	2+	-	3+
AB-25/AB-94	LC	2+	-	3+	-	-	+

10 PCR products generated with *Pfu* were a very small amount of Fd with AB-61 and AB-62 from PBL template and Fd with AB-63 and CH1 from 9F12 template. PCR products generated with *Taq* were Fd with all 5' primers and CH1 PBL and 9F12 templates and LC with 9F12 template. PCR products generated with *Pfu* and *Taq* were Fd with AB-61, AB-62, AB-64, CH1, and LC from PBL template. PCR products

15 generated with *Pfu* and *Taq* were Fd with AB-62, AB-63, AB-64, CH1, and LC from 9F12 template. In general, the results with the PBL template had a lot of failure products and there was significantly more product with the 9F12 template.

The inability of *Pfu* DNA polymerase to extend from any of the 5' primers other than AB-63 may be due to internal mismatches with 9F12 as the template and not be

20 due to the 3' primer:template mismatches.

EXAMPLE 6

The effect of a combination of four different polymerases in seven different buffers was tested on three different templates. The desired effects were an increase in the amount of PCR product generated and/or an increased specificity of amplification.

No effect was observed between using a combination of four polymerases and *Taq* DNA polymerase in the buffers tested.

Seven different templates with eight different primer sets were used in this experiment. The genomic DNAs were isolated from human, Epstein Barr virus, *Escherichia coli*, and transgenic and normal mouse. Plasmid DNAs were pBluescript II and pBluescript containing the light chain and Fd of an anti-tetanus toxoid immunoglobulin (Mullinax et al., 1990, supra). Primer sequences and their respective DNA templates are given in Table 16. The thermostable polymerases used in this experiment were *Taq*, *Exo⁺* and *Exo⁻* *Pfu*, and ES-4 DNA polymerases (Stratagene; La Jolla, California) at final concentrations of 2.5, 1.25, 1.25, and 0.125 units per reaction, respectively. PCR reactions were at a primer concentration of 0.2 μ M of each 5' and 3' primer in 1x *Taq* buffer, 1x *Pfu* #1, or 1x *Pfu* #3 (Table 17) with 200 μ M each dNTP. An additional reaction with *Taq* DNA polymerase in 1x *Taq* buffer was also performed. Samples were denatured at 95°C for 5 minutes and annealed at 40°C for 5 minutes followed by PCR amplification at 95°C for 0.5 minutes, 40°C for 1.5 minutes and 68°C for 3 minutes for 25 cycles. Samples were analyzed as previously described and results are not given.

Results indicated that no significant increase in the amount of PCR product generated or an increase in specificity was observed when comparing *Taq* DNA polymerase in *Taq* buffer and a combination of polymerases in the three different buffers tested. Results seemed to correlate with the buffer used and not the polymerase.

EXAMPLE 7

TAQ AND PFU DNA POLYMERASES IN SPLICE OVERLAP EXTENSION REACTIONS TO GENERATE CLONING VECTORS

A series of lambda-based vectors were constructed to express immunoglobulin fragments on the surface of M13 phage. The example described below describes the construction of one of these vectors. *Pfu* and *Taq* DNA polymerases in combination were used to construct this vector because of the high processivity of *Taq* DNA polymerase and the high fidelity of *Pfu* DNA polymerase. The nucleotide sequence of the cpVIII expression vector matched the expected nucleotide sequence.

cpVIII expression vector construction

Oligonucleotide primers used to construct the IZ H-8 (-1 to 50) vector with the cpVIII protein domain were designed to encode the following: an Xho I restriction site, stop codons, nucleotide spacer sequences, an Xba I site that generates an amber codon,
5 amino acids -1 to 50 of cpVIII, stop codons, and a Spe I restriction site.

Nucleotide sequences of the primers used to amplify cpVIII from M13 Phagescript DNA (Stratagene; La Jolla, California) using the 5' and 3' cpVIII primers are given in Table 19. All PCR reactions were at a primer concentration of 0.2 μ M of each 5' and 3' primer in 1x V25 buffer with 200 μ M each dNTP and 2.5 units each *Taq*
10 and *Pfu* DNA polymerases. Samples were denatured at 95°C for 5 minutes and annealed at 54°C for 5 minutes followed by PCR amplification at 74°C for 3 minutes, 93°C for 1.5 minutes and 54°C for 2.5 minutes for 30 cycles.

The cpVIII encoding PCR product was restriction digested with Xho I and Spe I and ligated into the IZ H vector (Stratagene; La Jolla, California; Huse, W.D., L. Sastry,
15 S.A. Iverson, A.S. Kang, M. Alting-Mees, D.R. Burton, S.J. Benkovic, and R.A. Lerner. Generation of a large combinatorial library of the immunoglobulin repertoire in phage lambda. 1989. *Science*. 246:1275-1281) which had previously been restriction digested with Xho I and Spe I. The ligation products were packaged with Gigapack II® Gold (Stratagene; La Jolla, California) and plated with XL1-Blue host cells. The desired
20 construct was identified by PCR amplification of isolated phage cores with the 5' and 3' cpVIII cloning primers, converted to the plasmid format by *in vivo* excision with VCS M13 helper phage (Short, J., J.M Fernandez, J.A. Sorge, and W.D. Huse, Lambda ZAP: a bacteriophage lambda vector with *in vitro* excision proprieties, 1988, *Nucleic Acids Res.* 16:7583-7600) and the nucleotide sequence was determined by the dideoxy method.
25 The nucleotides was sequence as expected.

Table 12
HUMAN HEAVY CHAIN PCR PRIMERS
WITH MATCHED AND 3' MISMATCHES VH PRIMERS

	primer	description	nucleotide sequence (5' to 3')
5	AB-205	5' VH	GTCCTGTCCGAGGTGCAGCTGCTCGAGTCTG G (SEQ ID NO: 1)
	AB-61	5' VH	AGGTGCAGCTGCTCGAGTCTGG (SEQ ID NO: 2)
	AB-714	5' VH	AGGTGCAGCTGCTCGAGTCTGT (SEQ ID NO: 3)
	AB-715	5' VH	AGGTGCAGCTGCTCGAGTCTTT (SEQ ID NO: 4)
	AB-716	5' VH	AGGTGCAGCTGCTCGAGTCTGGT (SEQ ID NO: 5)
10	AB-717	5' VH	AGGTGCAGCTGCTCGAGTCTGTT (SEQ ID NO: 6)
	AB-76	3' CH1	AGCATCACTAGTACAAGATTGGGCTC (SEQ ID NO: 7)
	AB-52	3' CH1	CGGGAGATCATGAGGGTGTCTT (SEQ ID NO: 8)
	MK-39	3' VH	ATATACTAGTGAGACAGTGACCAGGGTTCC TTGGCCCCA (SEQ ID NO: 9)

Table 13

HUMAN HEAVY AND LIGHT CHAIN PCR PRIMERS

	primer	description	nucleotide sequence (5' to 3')
	AB-205	5' VH	GTCCTGTCCGAGGTGCAGCTGCTCGAGTCTGG (SEQ ID NO: 1)
5	AB-61	5' VH	AGGTGCAGCTGCTCGAGTCTGG (SEQ ID NO: 2)
	AB-714	5' VH	AGGTGCAGCTGCTCGAGTCTGT (SEQ ID NO: 3)
	AB-715	5' VH	AGGTGCAGCTGCTCGAGTCTTT (SEQ ID NO: 4)
	AB-716	5' VH	AGGTGCAGCTGCTCGAGTCTGGT (SEQ ID NO: 5)
	AB-717	5' VH	AGGTGCAGCTGCTCGAGTCTGTT (SEQ ID NO: 6)
10	AB-76	3' CH1	AGCATCACTAGTACAAGATTGGGCTC (SEQ ID NO: 7)
	AB-52	3' CH1	CGGGAGATCATGAGGGTGTCTT (SEQ ID NO: 8)
	MK-39	3' VH	ATATACTAGTGAGACAGTGACCAGGGTTCC TTGGCCCA (SEQ ID NO: 9)
	AB-25	5' VL	GTGCCAGATGTGAGCTCGTGATGACCCAGT CTCCA (SEQ ID NO: 10)
	AB-94	3' CL	TCCTTCTAGATTACTAACACTCTCCCCTGTT GAAGCTCTTTGTGACGGGCGAACTC (SEQ ID NO: 11)
15	MK-94	5' CH1	GTCTCACTAGTCTCCACCAAGGGCCCATCGG TC (SEQ ID NO: 12)
	AB-58	3' CH2	CGGGAGATCATGAGGGTGTCTT (SEQ ID NO: 13)
	MK-25	5' CH2	CTCAGTATGGTGGTTGTGC (SEQ ID NO: 14)

primer	description	nucleotide sequence (5' to 3')
MK-26	3' CH3	CCGGAATTCTTATCATTACCCGGAGA (SEQ ID NO: 15)

- nucleotides in bold indicate where dTTP was introduced into the AB-61 primer

Table 14
pBluescript PCR primers

description	nucleotide sequence (5' to 3')
T3	ATTAACCCTCACTAAAG (SEQ ID NO: 16)
T7	AATACGACTCACTATAG (SEQ ID NO: 17)

5

Table 15

MOUSE HEAVY AND LIGHT CHAIN PCR PRIMERS

primer	description	nucleotide sequence (5' to 3')
AB-25	5' VL <i>kappa</i>	GTGCCAGATGTGAGCTCGTGATGACCC AGTCTCCA (SEQ ID NO: 10)
AB-26	3' CL <i>kappa</i>	TCCTTCTAGATTACTAACACTCTCCCCT GTTGAA (SEQ ID NO: 18)
AB-28	5' VL <i>lambda</i>	CTGCACAGGGTCCTGGGCCGAGCTCGT GGTGACTCAG (SEQ ID NO: 19)
AB-92	3' VL <i>lambda</i>	GCATTCTAGACTATTAACATTCTGTAGG GGC (SEQ ID NO: 20)
AB-19	5' VH	AGGTCCAGCTGCTCGAGTCTGG (SEQ ID NO: 21)
AB-41	3' CH1	AGGCTTACTAGTACAATCCCTGGGCAC AAT (SEQ ID NO: 22)
MK-501	3' VH	CCGTTACTAGTAGCCAAAACGACACCC CCATCTGTC (SEQ ID NO: 23)

Table 16
DNA TEMPLATES AND PCR PRIMER SEQUENCES

	template description	primer description	nucleotide sequence (5' to 3')
5	human	5' Gaucher's disease	CCTGAGGGCTCCCAGAGAGT GG (SEQ ID NO: 24)
	human	3' Gaucher's disease	GGTTTAGCACGACCACAACA GC (SEQ ID NO: 25)
	pBluescript KS+	5' multiple cloning site	ATTAACCCTCACTAAA (SEQ ID NO: 26)
	pBluescript KS+	3' multiple cloning site	AATACGACTCACTATAG (SEQ ID NO: 27)
	Epstein Barr virus	5' nuc antigen gene	GGCTGGTGTCACCTGTGTTA (SEQ ID NO: 28)
10	Epstein Barr virus	3' nuc antigen gene	CCTTAGGAGGAACAAGTCCC (SEQ ID NO: 29)
	<i>E. coli</i>	5' RNase H gene	CTTGAAGATCTATGCTTAAA CAGGTAG (SEQ ID NO: 30)
	<i>E. coli</i>	3' RNase H gene	CATGTGAATTCTTAACTTC AACTTGG (SEQ ID NO: 31)
	transgenic mouse	5' lambda lacZ insert	GGTGGCGACGACTCCTGGAG CCC (SEQ ID NO: 32)
	transgenic mouse	3' lambda lacZ insert	GACAGTCACTCCGGCCCGTG CGG (SEQ ID NO: 33)
15	human	5' fucosidase gene	AAGCTTCAGGAAAACAGTG AGCAGCGCCTC (SEQ ID NO: 34)
	human	3' fucosidase gene	AGTCAGGTATCTTTGACAGT (SEQ ID NO: 35)

5	nontransgenic mouse	5' B-adrenergic receptor	GGAATTCGTAACAGCACTTA CGGTAGC (SEQ ID NO: 36)
	nontransgenic mouse	3' B-adrenergic receptor	AGCACTCATAAGTGACACCC (SEQ ID NO: 37)
	transgenic mouse	5' lambda lacI insert	CATAGCGAATTCGCAAAACC TTTCGCGGTATGG (SEQ ID NO: 38)
	transgenic mouse	3' lambda lacI insert	ACTACGGAATTCCACGGAAA ATGCCGCTCATCC (SEQ ID NO: 39)

Table 17
10x PCR BUFFER COMPONENTS

10	component	<i>Taq</i>	V25	<i>Pfu</i> #1	<i>Pfu</i> #3
	KCl	500 mM	100 mM	100 mM	100 mM
	(NH ₄) ₂ SO ₄		60 mM	60 mM	100 mM
	tris-Cl, pH 8.8	100 mM			
15	tris-Cl, pH 8.2		200 mM	200 mM	
	tris-Cl, pH 8.5				200 mM
	MgCl ₂	15 mM	15 mM	20 mM	15 mM
	MgSO ₄				20 mM
20	Triton X-100		1%(v/v)	1%(v/v)	1%(v/v)
	bovine serum albumin		100 μg/ml	100 μg/ml	1 mg/ml
	gelatin	0.01% (w/v)			

Table 18
HUMAN VH PCR PRIMERS

primer	description	nucleotide sequence (5' to 3')
AB-61	5' VH	AGGTGCAGCTGCTCGAGTCTGG (SEQ ID NO: 2)
AB-62	5' VH	AGGTGCAGCTGCTCGAGTCGGG (SEQ ID NO: 40)
AB-63	5' VH	AGGTGCAACTGCTCGAGTCTGG (SEQ ID NO: 41)
AB-64	5' VH	AGGTGCAACTGCTCGAGTCGGG (SEQ ID NO: 42)

Table 19

OLIGONUCLEOTIDE PRIMERS USED TO CONSTRUCT

THE IZ H-8 (-1 to 50) VECTOR

5' cpVIII	TTGACTCGAGTAATCTGAGCTAAAGTCTAGAGCGCTGAGGGTG ACGATCC (SEQ ID NO: 43)
5 3' cpVIII	ATGGCAACTAGTTATCAGCTTGCTTTCGAGG (SEQ ID NO: 44)

EQUIVALENTS

All publications and patent applications mentioned in this specification are indicative of the level of skill of those skilled in the art to which this invention pertains. All publications and patent applications are herein incorporated by reference to the same
5 extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.

The foregoing written specification is considered to be sufficient to enable one skilled in the art to practice the invention. Indeed, various modifications of the above-described modes for carrying out the invention which are obvious to those skilled in the
10 field of molecular biology or related fields are intended to be within the scope of the following claims.

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) **APPLICANT:** Sorge, Joseph A.
Mullinax, Rebecca L.

(ii) **TITLE OF INVENTION:** NOVEL POLYMERASE COMPOSITIONS AND
USES THEREOF

(iii) **NUMBER OF SEQUENCES:** 44

(iv) **CORRESPONDENCE ADDRESS:**

(A) **ADDRESSEE:** Limbach and Limbach
(B) **STREET:** 2001 Ferry Building
(C) **CITY:** San Francisco
(D) **STATE:** CA
(E) **COUNTRY:** USA
(F) **ZIP:** 94111

(v) **COMPUTER READABLE FORM:**

(A) **MEDIUM TYPE:** Floppy disk
(B) **COMPUTER:** IBM PC compatible
(C) **OPERATING SYSTEM:** PC-DOS/MS-DOS
(D) **SOFTWARE:** PatentIn Release #1.0, Version #1.25

(vi) **CURRENT APPLICATION DATA:**

(A) **APPLICATION NUMBER:** US
(B) **FILING DATE:**
(C) **CLASSIFICATION:**

(vii) **PRIOR APPLICATION DATA:**

(A) **APPLICATION NUMBER:** US 08/164,290
(B) **FILING DATE:** 08-DEC-1993

(viii) **ATTORNEY/AGENT INFORMATION:**

(A) **NAME:** Bortner, Scott R.
(B) **REGISTRATION NUMBER:** 34,298
(C) **REFERENCE/DOCKET NUMBER:** STRG 20270 USA

(ix) **TELECOMMUNICATION INFORMATION:**

(A) **TELEPHONE:** 415-433-4150
(B) **TELEFAX:** 415-433-8716

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 32 base pairs**
- (B) TYPE: nucleic acid**
- (C) STRANDEDNESS: single**
- (D) TOPOLOGY: linear**

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

GTCCTGTCCG AGGTGCAGCT GCTCGAGTCT GG

32

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 22 base pairs**
- (B) TYPE: nucleic acid**
- (C) STRANDEDNESS: single**
- (D) TOPOLOGY: linear**

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

AGGTGCAGCT GCTCGAGTCT GG

22

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 22 base pairs**
- (B) TYPE: nucleic acid**
- (C) STRANDEDNESS: single**
- (D) TOPOLOGY: linear**

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

AGGTGCAGCT GCTCGAGTCT GT

22

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 22 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

AGGTGCAGCT GCTCGAGTCT TT

22

(2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 23 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

AGGTGCAGCT GCTCGAGTCT GGT

23

(2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 23 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

AGGTGCAGCT GCTCGAGTCT GTT

23

(2) INFORMATION FOR SEQ ID NO:7:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 27 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

AGCATCACTA GTACAAGATT TGGGCTC

27

(2) INFORMATION FOR SEQ ID NO:8:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 23 base pairs**
- (B) TYPE: nucleic acid**
- (C) STRANDEDNESS: single**
- (D) TOPOLOGY: linear**

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

CGGGAGATCA TGAGGGTGTC CTT

23

(2) INFORMATION FOR SEQ ID NO:9:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 39 base pairs**
- (B) TYPE: nucleic acid**
- (C) STRANDEDNESS: single**
- (D) TOPOLOGY: linear**

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

ATATACTAGT GAGACAGTGA CCAGGGTTCC TTGGCCCCA
39

(2) INFORMATION FOR SEQ ID NO:10:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 35 base pairs**
- (B) TYPE: nucleic acid**
- (C) STRANDEDNESS: single**
- (D) TOPOLOGY: linear**

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

GTGCCAGATG TGAGCTCGTG ATGACCCAGT CTCCA
35

(2) INFORMATION FOR SEQ ID NO:11:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 56 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

TCCTTCTAGA TTACTAACAC TCTCCCCTGT TGAAGCTCTT TGTGACGGGC
GAACTC 56

(2) INFORMATION FOR SEQ ID NO:12:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 33 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

GTCTCACTAG TCTCCACCAA GGGCCCATCG GTC

33

(2) INFORMATION FOR SEQ ID NO:13:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 23 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

CGGGAGATCA TGAGGGTGTC CTT

23

(2) INFORMATION FOR SEQ ID NO:14:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 19 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

CTCAGTATGG TGGTTGTGC

19

(2) INFORMATION FOR SEQ ID NO:15:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 27 base pairs**
- (B) TYPE: nucleic acid**
- (C) STRANDEDNESS: single**
- (D) TOPOLOGY: linear**

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

CCGGAATTCT TATCATTAC CCGGAGA

27

(2) INFORMATION FOR SEQ ID NO:16:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 17 base pairs**
- (B) TYPE: nucleic acid**
- (C) STRANDEDNESS: single**
- (D) TOPOLOGY: linear**

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

ATTAACCCTC ACTAAAG

17

(2) INFORMATION FOR SEQ ID NO:17:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 17 base pairs**
- (B) TYPE: nucleic acid**
- (C) STRANDEDNESS: single**

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:

AATACGACTC ACTATAG

17

(2) INFORMATION FOR SEQ ID NO:18:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 34 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:

TCCTTCTAGA TTACTAACAC TCTCCCCTGT TGAA

34

(2) INFORMATION FOR SEQ ID NO:19:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 37 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:

CTGCACAGGG TCCTGGGCCG AGCTCGTGGT GACTCAG
37

(2) INFORMATION FOR SEQ ID NO:20:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 31 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:

GCATTCTAGA CTATTAACAT TCTGTAGGGG C

31

(2) INFORMATION FOR SEQ ID NO:21:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 22 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:

AGGTCCAGCT GCTCGAGTCT GG

22

(2) INFORMATION FOR SEQ ID NO:22:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 30 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:

AGGCTTACTA GTACAATCCC TGGGCACAAT

30

(2) INFORMATION FOR SEQ ID NO:23:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 36 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:

CCGTTACTAG TAGCCAAAAC GACACCCCCA TCTGTC
36

(2) INFORMATION FOR SEQ ID NO:24:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 22 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:

CCTGAGGGCT CCCAGAGAGT GG

22

(2) INFORMATION FOR SEQ ID NO:25:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 22 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:25:

GGTTTAGCAC GACCACAACA GC

22

(2) INFORMATION FOR SEQ ID NO:26:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 17 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:26:

AATACGACTC ACTATAG

17

(2) INFORMATION FOR SEQ ID NO:27:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 17 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:27:

AATACGACTC ACTATAG

17

(2) INFORMATION FOR SEQ ID NO:28:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:28:

GGCTGGTGTC ACCTGTGTTA

20

(2) INFORMATION FOR SEQ ID NO:29:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:29:

CCTTAGGAGG AACAAAGTCCC

20

(2) INFORMATION FOR SEQ ID NO:30:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 27 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:30:

CTTGAAGATC TATGCTTAAA CAGGTAG

27

(2) INFORMATION FOR SEQ ID NO:31:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 27 base pairs**
- (B) TYPE: nucleic acid**
- (C) STRANDEDNESS: single**
- (D) TOPOLOGY: linear**

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:31:

CATGTGAATT CTTAACTTC AACTTGG

27

(2) INFORMATION FOR SEQ ID NO:32:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 23 base pairs**
- (B) TYPE: nucleic acid**
- (C) STRANDEDNESS: single**
- (D) TOPOLOGY: linear**

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:32:

GGTGGCGACG ACTCCTGGAG CCC

23

(2) INFORMATION FOR SEQ ID NO:33:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 23 base pairs**
- (B) TYPE: nucleic acid**
- (C) STRANDEDNESS: single**
- (D) TOPOLOGY: linear**

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:33:

GACAGTCACT CCGGCCCGTG CGG

23

(2) INFORMATION FOR SEQ ID NO:34:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 30 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:34:

AAGCTTCAGG AAAACAGTGA GCAGCGCCTC

30

(2) INFORMATION FOR SEQ ID NO:35:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:35:

AGTCAGGTAT CTTTGACAGT

20

(2) INFORMATION FOR SEQ ID NO:36:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 27 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:36:

GGAATTCGTA ACAGCACTTA CGGTAGC

27

(2) INFORMATION FOR SEQ ID NO:37:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:37:

AGCACTCATA AGTGACACCC

20

(2) INFORMATION FOR SEQ ID NO:38:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 33 base pairs**
- (B) TYPE: nucleic acid**
- (C) STRANDEDNESS: single**
- (D) TOPOLOGY: linear**

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:38:

CATAGCGAAT TCGCAAACC TTTCGCGGTA TGG

33

(2) INFORMATION FOR SEQ ID NO:39:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 33 base pairs**
- (B) TYPE: nucleic acid**
- (C) STRANDEDNESS: single**
- (D) TOPOLOGY: linear**

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:39:

ACTACGGAAT TCCACGGAAA ATGCCGCTCA TCC

33

(2) INFORMATION FOR SEQ ID NO:40:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 22 base pairs**
- (B) TYPE: nucleic acid**
- (C) STRANDEDNESS: single**
- (D) TOPOLOGY: linear**

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:40:

AGGTGCAGCT GCTCGAGTCG GG

22

(2) INFORMATION FOR SEQ ID NO:41:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 22 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:41:

AGGTGCAACT GCTCGAGTCT GG

22

(2) INFORMATION FOR SEQ ID NO:42:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 22 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:42:

AGGTGCAACT GCTCGAGTCG GG

22

(2) INFORMATION FOR SEQ ID NO:43:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 50 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:43:

TTGACTCGAG TAATCTGAGC TAAAGTCTAG AGCGCTGAGG GTGACGATCC
50

(2) INFORMATION FOR SEQ ID NO:44:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 31 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:44:

ATGGCAACTA GTTATCAGCT TGCTTTCGAG G

31

CLAIMS

What is claimed is:

1. A composition comprising a mixture containing:
 - (a) an enzyme possessing substantial 3'-5' exonuclease activity, and
 - (b) a DNA polymerase, wherein said polymerase has less 3'-5' exonuclease activity than said enzyme.
2. A composition according to Claim 1, wherein said enzyme is a DNA polymerase.
3. A composition according to Claim 1, wherein said polymerase and said enzyme possessing substantial 3'-5' exonuclease activity are thermostable.
4. A composition according to Claim 3, wherein said enzyme possessing substantial 3'-5' exonuclease activity is a DNA polymerase.
5. A composition according to Claim 3, wherein said DNA polymerase substantially with less 3'-5' exonuclease activity is Taq polymerase.
6. A composition according to claim 1, wherein said enzyme possessing substantial 3'-5' exonuclease activity is selected from the group consisting of *Pfu* polymerase, *E. coli* DNA polymerase I, Klenow fragment, T-4 polymerase, T-7 polymerase, Vent polymerase, and Deep Vent polymerase.
7. A composition according to claim 3, wherein said enzyme possessing substantial 3'-5' exonuclease activity is selected from the group consisting of *Pfu* polymerase, Vent polymerase, and Deep Vent polymerase.
8. A composition according to Claim 5, wherein said enzyme possessing substantial 3'-5' exonuclease activity is *Pfu* polymerase.

9. A method of synthesizing a polynucleotide comprising the step of mixing a composition according to claim 1 with a synthesis primer, and a synthesis template.
10. A method according to Claim 9, wherein said enzyme possessing substantial 3'-5' exonuclease activity is a DNA polymerase.
11. A method according to Claim 9, wherein said polymerase and said enzyme possessing substantial 3'-5' exonuclease activity are thermostable.
12. A method according to Claim 11, wherein said enzyme possessing substantial 3'-5' exonuclease activity is a DNA polymerase.
13. A method according to Claim 11, wherein said DNA polymerase with less 3'-5' exonuclease activity is Taq polymerase.
14. A method according to claim 9, wherein said enzyme possessing substantial 3'-5' exonuclease activity is selected from the group consisting of *Pfu* polymerase, *E. coli* DNA polymerase I, Klenow fragment, T-4 polymerase, T-7 polymerase, Vent polymerase, and Deep Vent polymerase.
15. A method according to claim 11, wherein said enzyme possessing substantial 3'-5' exonuclease activity is selected from the group consisting of *Pfu* polymerase, Vent polymerase, and Deep Vent polymerase.
16. A method according to Claim 13, wherein said enzyme possessing substantial 3'-5' exonuclease activity is *Pfu* polymerase.
17. A method of amplifying a polynucleotide sequence in a cyclic amplification reaction, said method comprising, synthesizing a polynucleotide by the method of Claim 9.

18. A method of amplifying a polynucleotide sequence with a cyclic amplification reaction said method comprising, synthesizing a polynucleotide by the method of Claim 10.
19. A method of amplifying a polynucleotide sequence with a cyclic amplification reaction said method comprising, synthesizing a polynucleotide by the method of Claim 11.
20. A method of amplifying a polynucleotide sequence with a cyclic amplification reaction said method comprising, synthesizing a polynucleotide by the method of Claim 12.
21. A method of amplifying a polynucleotide sequence with a cyclic amplification reaction said method comprising, synthesizing a polynucleotide by the method of Claim 13.
22. A method of amplifying a polynucleotide sequence with a cyclic amplification reaction said method comprising, synthesizing a polynucleotide by the method of Claim 14.
23. A method of amplifying a polynucleotide sequence with a cyclic amplification reaction said method comprising, synthesizing a polynucleotide by the method of Claim 15.
24. A method of amplifying a polynucleotide sequence with a cyclic amplification reaction said method comprising, synthesizing a polynucleotide by the method of Claim 16.
25. A kit for the synthesis of a polynucleotide, said kit comprising, a mixture containing:

- (a) a DNA polymerase, wherein said polymerase is substantially with less 3'-5' exonuclease activity, and
- (b) an enzyme possessing substantial 3'-5' exonuclease activity.
26. A kit according to Claim 25, wherein said enzyme possessing substantial 3'-5' exonuclease activity is a DNA polymerase.
27. A kit according to Claim 25, wherein said polymerase and said enzyme possessing substantial 3'-5' exonuclease activity are thermostable.
28. A kit according to Claim 27, wherein said enzyme possessing substantial 3'-5' exonuclease activity is a DNA polymerase.
29. A kit according to Claim 27, wherein said DNA polymerase substantially with less 3'-5' exonuclease activity is Taq polymerase.
30. A kit according to claim 25, wherein said enzyme possessing substantial 3'-5' exonuclease activity is selected from the group consisting of *Pfu* polymerase, *E. coli* DNA polymerase I, Klenow fragment, T-4 polymerase, T-7 polymerase, Vent polymerase, and Deep Vent polymerase.
31. A kit according to claim 28, wherein said enzyme possessing substantial 3'-5' exonuclease activity is selected from the group consisting of *Pfu* polymerase, Vent polymerase, and Deep Vent polymerase.
32. A kit according to Claim 29, wherein said enzyme possessing substantial 3'-5' exonuclease activity is *Pfu* polymerase.

A. CLASSIFICATION OF SUBJECT MATTER IPC 6 C12N9/12 C12Q1/68		PCT/US 94/14003		
According to International Patent Classification (IPC) or to both national classification and IPC				
B. FIELDS SEARCHED				
Minimum documentation searched (classification system followed by classification symbols) IPC 6 C12N C12Q				
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched				
Electronic data base consulted during the international search (name of data base and, where practical, search terms used)				
C. DOCUMENTS CONSIDERED TO BE RELEVANT				
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.		
X	NUCLEIC ACIDS RESEARCH, vol.19, no.9, 1991, ARLINGTON, VIRGINIA US page 2511	1,9,25		
Y	YU SHENG ZHU ET AL. 'THE USE OF EXONUCLEASE...' see the whole document	2-8, 10-24, 26-32		
Y	--- WO,A,92 09689 (STRATAGENE) 11 June 1992 see page 3, line 31 - page 5, line 5	2-8, 10-24, 26-32		
Y	--- EP,A,0 502 589 (HOFFMANN LA ROCHE) 9 September 1992 see page 7, line 1 - line 3; claim 11 -----	2-8, 10-24, 26-32		
<input type="checkbox"/> Further documents are listed in the continuation of box C.				
<input checked="" type="checkbox"/> Patent family members are listed in annex.				
* Special categories of cited documents :				
<table style="width: 100%; border: none;"> <tr> <td style="width: 50%; vertical-align: top; padding: 5px;"> *A* document defining the general state of the art which is not considered to be of particular relevance *E* earlier document but published on or after the international filing date *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) *O* document referring to an oral disclosure, use, exhibition or other means *P* document published prior to the international filing date but later than the priority date claimed </td> <td style="width: 50%; vertical-align: top; padding: 5px;"> *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. *Z* document member of the same patent family </td> </tr> </table>			*A* document defining the general state of the art which is not considered to be of particular relevance *E* earlier document but published on or after the international filing date *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) *O* document referring to an oral disclosure, use, exhibition or other means *P* document published prior to the international filing date but later than the priority date claimed	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. *Z* document member of the same patent family
A document defining the general state of the art which is not considered to be of particular relevance *E* earlier document but published on or after the international filing date *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) *O* document referring to an oral disclosure, use, exhibition or other means *P* document published prior to the international filing date but later than the priority date claimed	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. *Z* document member of the same patent family			
Date of the actual completion of the international search <div style="text-align: center; font-weight: bold;">3 May 1995</div>	Date of mailing of the international search report <div style="text-align: center; font-weight: bold;">18 -05- 1995</div>			
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax (+31-70) 340-3016	Authorized officer <div style="text-align: center; font-weight: bold;">Gurdjian, D</div>			

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A-9209689	11-06-92	AU-A- 9165991 WO-A- 9209200	25-06-92 11-06-92
EP-A-0502589	09-09-92	US-A, B 4683202 US-A- 4683195 AU-B- 586233 AU-A- 5532286 AU-B- 591104 AU-A- 5532386 CA-A- 1237685 DE-A- 3687287 DE-A- 3687537 DE-T- 502588 DK-A- 26595 EP-A, B 0200362 EP-A, B 0201184 EP-A- 0502588 EP-A- 0509612 EP-A- 0505012 HK-A- 84094 HK-A- 84994 JP-B- 4067957 JP-A- 62000281 JP-B- 4067960 JP-A- 61274697 JP-A- 6007166 JP-A- 5308971 US-A- 5386022 US-A- 5176995 US-A- 4800159	28-07-87 28-07-87 06-07-89 02-10-86 30-11-89 02-10-86 07-06-88 28-01-93 04-03-93 16-12-93 17-03-95 05-11-86 12-11-86 09-09-92 21-10-92 23-09-92 26-08-94 26-08-94 29-10-92 06-01-87 29-10-92 04-12-86 18-01-94 22-11-93 31-01-95 05-01-93 24-01-89